Try our Advanced Search for more refined results

United States of America et al v. Celgene Corporation

  1. November 14, 2017

    DOJ Fights Whistleblower 'Windfall' In $280M FCA Deal

    The U.S. Department of Justice told a California federal court Monday not to award a whistleblower $78 million of a $280 million settlement for her work in prosecuting a False Claims Act suit against Celgene Corp. over the alleged promotion of off-label uses for two cancer drugs, saying $65 million is enough.

  2. July 25, 2017

    Celgene To Pay $280M To End Off-Label Cancer Drug FCA Suit

    Celgene Corp. has agreed to shell out $280 million to end a False Claims Act suit launched in California by a whistleblower who accused the drug company of promoting off-label uses for two cancer drugs, federal prosecutors announced on Tuesday.

  3. January 31, 2017

    Celgene Says 9th Circ. Ruling Means $40B FCA Suit Must Go

    Celgene on Monday urged a California federal judge to reconsider his refusal to throw out a $40 billion False Claims Act suit accusing the pharmaceutical company of overcharging Medicare and Medicaid for cancer drugs, arguing that a recent Ninth Circuit ruling requires the court to apply a legal standard the relator cannot satisfy.

  4. October 13, 2016

    Escobar Supports Nixing $40B FCA Suit, Celgene Says

    A trio of rulings based on the U.S. Supreme Court's landmark Escobar decision in June show the government's continued reimbursement for cancer drugs Thalomid and Revlimid render a $40 billion False Claims Act suit against their maker Celgene immaterial, the pharmaceutical company told a California federal judge Wednesday.

  5. September 27, 2016

    Sales Rep Wants Docs Public In $40B Celgene FCA Row

    Celgene Corp. hasn't proven that documents it wants to seal in a $40 billion False Claims Act suit over off-label promotion of the cancer drugs Thalomid and Revlimid would be harmful if released, especially as some of them are already public, a whistleblower told a California federal court Monday.

  6. September 07, 2016

    Celgene Knocks Feds' Support Of $40B Off-Label FCA Suit

    The federal government's statement supporting a whistleblower's $40 billion False Claims Act suit against Celgene Corp. over the off-label promotion of cancer drugs Thalomid and Revlimid doesn't dismantle the company's arguments for dismissal because there's still no evidence of wrongdoing, Celgene told a California federal court Tuesday.

  7. August 30, 2016

    Celgene Battles $40B FCA Suit Over Off-Label Promos

    Celgene Corp. on Monday pressed a California federal judge to end a whistleblower's $40 billion False Claims Act suit over off-label promotion of cancer drugs Thalomid and Revlimid, asserting that government officials knew about off-label uses and didn't object.

  8. October 07, 2015

    Celgene Trying To Skirt $700M In FCA Claims, Relator Says

    A whistleblower on Wednesday blasted Celgene Corp.'s bid to exclude evidence in a False Claims Act suit over alleged off-label marketing of two cancer drugs, telling a California federal court the pharmaceutical company was simply trying to evade $700 million in damages owed to several states and the federal government.

  9. October 06, 2015

    Celgene Can't Limit Claims In FCA Off-Label Marketing Row

    A California federal judge on Tuesday denied a bid made by Celgene Corp. to halve the time period covered by a whistleblower's False Claims Act suit over alleged off-label marketing of cancer drugs Thalomid and Revlimid and related kickbacks to doctors.

  10. August 25, 2015

    Celgene Says High Court Ruling Limits Length Of FCA Suit

    The time period allowed in a whistleblower's False Claims Act suit against Celgene Corp. should be cut in half following the U.S. Supreme Court's ruling that a wartime pause on the expiration of government fraud claims does not apply to civil fraud cases, the company told a California federal court Monday.